期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

利伐沙班治疗急性门静脉血栓形成9例临床分析 被引量：1

Clinical Analysis of 9 Patients with Acute Portal Vein Thrombosis Treated by Rivaroxaban
下载PDF
导出
摘要 目的:探讨利伐沙班治疗急性门静脉血栓形成的疗效。方法:9例急性门静脉血栓形成病人(男性8例,女性1例)服用利伐沙班治疗,剂量10 mg,每日1次,观察门静脉复通时间、复通率及治疗期间的并发症。结果:门静脉复通平均时间36 d,其中8例完全复通,1例大部分复通。治疗期间未发现继发性出血等不良反应。结论:利伐沙班治疗急性门静脉血栓形成的疗效良好且使用方便。 Objective： To investigate the efficacy of Rivaroxaban in the treatment of acute portal vein thrombosis. Methods： 9 patients （8 men and 1 woman） with acute portal vein thrombosis were treated by Rivaroxaban with the dosage of 10 mg daily. The time and rate of recanalization and the complications during the anticoagulant therapy were observed. Results： The mean recanalization time of portal vein was 36 d. 8 cases had complete recanalization and the other one had partial recanalization. No sencondary bleeding happened during the anticoagulant therapy. Conclusion： The treatment with Rivaroxaban in the patients sufferring from acute portal vein thrombosis is safe and convenient.
作者 张红卫 陈亚进 黄泽坚 吴昶皓 李闻达
机构地区 中山大学孙逸仙纪念医院肝胆外科
出处 《岭南急诊医学杂志》 2013年第5期347-348,共2页 Lingnan Journal of Emergency Medicine
关键词 利伐沙班 门静脉 血栓形成 Rivaroxaban portal vein thrombosis
分类号 R657.3 [医药卫生—外科学]
  • 相关文献

参考文献2

二级参考文献48

  • 1蒋绚,刘玉兰,金鹏华,董玉柱.肝硬化门静脉血栓形成的临床分析[J].中华消化杂志,2004,24(6):329-331. 被引量：13
  • 2Vujic I.Vascular complications of pancreatitis.Radiol Clin North Am.1989;27:81-91.
  • 3Parikh S, Shah R, Kapoor P.Portal vein thrombosis.Am J Med.2010;123:111-119.
  • 4Ponziani FR, Zocco MA, Campanale C, Rinninella E, Tortora A, Di Maurizio L, Bombardieri G, De Cristofaro R, De Gaetano AM, Landolfi R.Portal vein thrombosis: insight into physiopathology, diagnosis, and treatment.World J Gastroenterol.2010;16:143-155.
  • 5Muckart DJ, Bade P.Pancreatic pseudocyst haemorrhage presenting as a bleeding duodenal ulcer.Postgrad Med J.1989;65:748-749.
  • 6Mortelé KJ, Mergo PJ, Taylor HM, Wiesner W, Cantisani V, Ernst MD,Kalantari BN, Ros PR.Peripancreatic vascular abnormalities complicating acute pancreatitis: contrast-enhanced helical CT findings.Eur J Radiol.2004;52:67-72.
  • 7D?rffel T, Wruck T, Rückert RI, Romaniuk P, D?rffel Q, Wermke W.Vascular complications in acute pancreatitis assessed by color duplex ultrasonography.Pancreas.2000;21:126-133.
  • 8Mendelson RM, Anderson J, Marshall M, Ramsay D.Vascular complications of pancreatitis.ANZ J Surg.2005;75:1073-1079.
  • 9Gonzelez HJ, Sahay SJ, Samadi B, Davidson BR, Rahman SH.Splanchnic vein thrombosis in severe acute pancreatitis: a 2-year, single-institution experience.HPB (Oxford).2011;13:860-864.
  • 10Mallick IH, Winslet MC.Vascular complications of pancreatitis.JOP.2004;5:328-337.

共引文献13

同被引文献19

  • 1Zhao X, Sun P, Cui Y, et al. Safety, pharmacokinetics and pharma- codynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjectsJ [J]. Br J Clin Pharmacol, 2009, 68(1): 77-88.
  • 2Jiang J, Hu Y, Hu P, et al. Safetyj pharmacokinetics and pharmacodynamics of single doses of rivaroxaban - an oral, direct factor Xa inhibitor - in elderly Chinese subjects[J]. Thromb Haemost, 2010, 103(1): 234-241.
  • 3Kubitza B, Becka M, Voith B, et al. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor[J]. Clin Pharmacol Ther, 2005, 78(4): 412-421.
  • 4Kubitza B, Becka M, Wensing G, et al. Safe~, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct Factor Xa inhibitor- after multiple dosing in healthy male subjects[J]. EurJ Clin Pharmacol, 2005, 61 (12): 873-880.
  • 5Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty[J]. N Engl J Med, 2008, 358(26): 2765-2775.
  • 6Lassen MR, Ageno W, Borris LC. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty[J]. N Engl J Med, 2008, 358(26): 2776-2786.
  • 7Buller I-IR, Prins MH, Segers A. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism[J]. N EnglJ Med, 2012, 366(14): 1287-1297.
  • 8Wang Y, Wang C, Chen Z, et al. Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies [J]. Thromb J, 2013, 11 ( 1 ): 25.
  • 9Patel MR, Mahaffey KW, Califf RM. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation[J]. N EnglJ Med, 2011, 365(10): 883- 891.
  • 10Mega JL, Braunwald E. Rivaroxaban in Patients with a Recent Acute Coronary Syndrome[J]. N EnglJ Med, 2012, 366: 9-19.

引证文献1

二级引证文献3

岭南急诊医学杂志
2013年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部